Universität zu Köln

Borchmann, Peter, Heger, Jan-Michel ORCID: 0000-0001-9463-8504, Mahlich, Jorg ORCID: 0000-0003-1110-2793, Papadimitrious, Michael S., Riou, Sybille and Werner, Barbara (2023). Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Health Claims Data Analysis. Oncol. Ther., 11 (1). S. 65 - 82. NEW YORK: SPRINGER. ISSN 2366-1089

Full text not available from this repository.

Abstract

Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma with increasing prevalence. Although the disease burden associated with DLBCL is high, only limited data on healthcare resource utilization (HCRU) and associated costs of German patients with DLBCL is available. Methods: Using a large claims database of the German statutory health insurance with 6.7 million enrollees, we identified patients who were newly diagnosed with DLBCL between 2011 and 2018 (index date). Treatment lines were identified based on a predefined set of medication. HCRU and related costs were collected for the entire post index period and per treatment line. Results: A total of 2495 incident DLBCL patients were eligible for the analysis. The average follow-up time after index was 41.7 months. During follow-up, 1991 patients started a first-line treatment, 868 a second-line treatment, and 354 a third-line treatment. Overall, patients spent on average (SD) 5.24 (6.17) days per month in hospital after index. While on anti-cancer treatment, this number increased to nine (10.9) in first-line, 8.7 (13.7) in second-line, and 9.4 (15.8) in third-line treatments. Overall costs per patient per month (PPPM) increased from (sic)421 (875.70) before to (sic)3695 (4652) after index. While on a treatment line, PPPM costs were (sic)17,170 (10,246) in first-line, (sic)13,362 (12,685) in second-line, and (sic)12,112 (16,173) in third-line treatments. Time-unadjusted absolute costs sum up to (sic)59,868 (43,331), (sic)35,870 (37,387), and (sic)28,832 (40,540) during first-line, second-line, and third-line treatments, respectively. The main cost drivers were hospitalizations (71% of total costs) and drug acquisition costs (18% of total costs). Conclusions: The financial burden of DLBCL in Germany is high, mainly due to hospitalization and drug costs. Therefore, there is a high medical need for new cost-effective therapeutic options that can lower the disease burden and remain financially viable to support the growing number of patients with this aggressive disease.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Borchmann, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Heger, Jan-Michel UNSPECIFIED orcid.org/0000-0001-9463-8504 UNSPECIFIED Mahlich, Jorg UNSPECIFIED orcid.org/0000-0003-1110-2793 UNSPECIFIED Papadimitrious, Michael S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Riou, Sybille UNSPECIFIED UNSPECIFIED UNSPECIFIED Werner, Barbara UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-676642
DOI:	10.1007/s40487-022-00211-6
Journal or Publication Title:	Oncol. Ther.
Volume:	11
Number:	1
Page Range:	S. 65 - 82
Date:	2023
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	2366-1089
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language FOLLICULAR LYMPHOMA; ECONOMIC BURDEN Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/67664